The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock

Intensive Care Medicine (Impact Factor: 7.21). 11/2009; 35(11):1868-1876. DOI: 10.1007/s00134-009-1603-4
Source: PubMed


RationaleUse of etomidate in the critically ill is controversial due to its links with an inadequate response to corticotropin and
potential for excess mortality. In a septic shock population, we tested the hypotheses that etomidate administration induces
more non-responders to corticotropin and increases mortality and that hydrocortisone treatment decreases mortality in patients
receiving etomidate.

MethodsAn a-priori sub-study of the CORTICUS multi-centre, randomised, double-blind, placebo-controlled trial of hydrocortisone in
septic shock. Use and timing of etomidate administration were collected. Endpoints were corticotropin response and all-cause
28-day mortality in patients receiving etomidate.

Measurements and main resultsFive hundred patients were recruited, of whom 499 were analysable; 96 (19.2%) were administered etomidate within the 72h
prior to inclusion. The proportion of non-responders to corticotropin was significantly higher in patients who were given
etomidate in the 72h before trial inclusion than in other patients (61.0 vs. 44.6%, P=0.004). Etomidate therapy was associated with a higher 28-day mortality in univariate analysis (P=0.02) and after correction for severity of illness (42.7 vs. 30.5%; P=0.06 and P=0.03) in our two multi-variant models. Hydrocortisone administration did not change the mortality of patients receiving
etomidate (45 vs. 40%).

ConclusionsThe use of bolus dose etomidate in the 72h before study inclusion is associated with an increased incidence of inadequate
response to corticotropin, but is also likely to be associated with an increase in mortality. We recommend clinicians demonstrate
extreme caution in the use of etomidate in critically ill patients with septic shock.

Download full-text


Available from: Didier Payen,

Click to see the full-text of:

Article: The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock

0 B

See full-text
  • Source
    • "Fig. 3. Mean arterial pressure before induction agent and up to 72 hours postinduction agent administration. transient period of etomidate-associated adrenal insufficiency [8] [9] [10] [11]. A retrospective cohort study including patients with severe sepsis and septic shock investigated the association between adrenal dysfunction and mortality and found that etomidate was associated with an increased mortality risk (OR, 1.53; 95% CI, 1.1-2.3), "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose The safety of single bolus etomidate to facilitate intubation in septic patients is controversial due to its potential to suppress adrenal steroidogenesis. The purpose of this study was to evaluate the effects of etomidate on the development of shock when used as an induction agent to facilitate intubation in septic patients. Methods A multi-center, retrospective, propensity-matched cohort study comparing patients with sepsis or severe sepsis who either received etomidate or did not receive etomidate for intubation was conducted. The primary outcome was the difference in the need for vasopressor support within 72 hours following intubation. Secondary outcomes included the use of multiple vasopressors, intensive care unit (ICU) length of stay (LOS), and in-hospital mortality. Results A total of 411 patients were analyzed. Eighty-three patients were matched by propensity score. There was no difference in the matched cohort in regards to vasopressor use within 72 hours of intubation (OR 0.95; 95% CI 0.52 – 1.76; p = 0.88). Furthermore, there were no significant differences observed with regards to secondary outcomes, including in-hospital mortality (p = 0.76). Conclusions The use of etomidate for intubation in septic patients did not increase vasopressor requirements within 72 hours following intubation.
    Journal of critical care 08/2014; 29(4). DOI:10.1016/j.jcrc.2014.02.002 · 2.00 Impact Factor
  • Source
    • "Etomidate is also a short-acting drug, which is commonly used for induction and maintenance of anesthesia.[13] The most important side-effects of Etomidate are nausea and vomiting that may lead to aspiration in patients.[141516] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Etomidate and Propofol are common anesthetic agents. Previous studies say that Etomidate can be used in patients with limited hemodynamic reserve and Propofol can lead to more hemodynamic instabilities. This study was performed to explore the cardiovascular response during the induction of anesthesia with Etomidate or for comparison, Propofol in elective orthopedic surgeries. This study was a double-blinded randomized clinical trial study including patients 18-45 years of age that were admitted for elective orthopedic surgeries in 2012. 25consenting, ASA I (American Society of Anaesthesiologists), patients were evaluated randomly in two groups, and their cardiovascular responses including: systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), and O2 saturation (O2 sat) were measured before the laryngoscopy, during the anesthesia induction with Etomidate (0.3 mg/kg) in group A and propfol (2-2.5 mg/kg) in group B and at 1, 3, 5,10 min after the induction. There were no statistical differences between both groups regarding gender, age, body mass index, and laryngoscopic grade of patients (P > 0.05). Changes of SBP in the group B was significantly higher (P = 0.019). Furthermore, changes of the DBP was significantly higher in the group B (P = 0.001). The changes of MAP was higher in group B (P = 0.008). Hypotension happened in 26.1% of group B and 8% of group A (P = 0.09). There were no significant differences among groups A and B in terms of HR (P = 0.47) and O2 sat (P = 0.21), tachycardia (P = 0.6), bradycardia (P = 0.66) and hypertension (P = 0.95). Since, patients receiving Etomidate have more stable hemodynamic condition, if there would be no contraindications, it could be preferred over Propofol for general anesthesia.
    Journal of research in medical sciences 10/2013; 18(10):870-4. · 0.65 Impact Factor
  • Source
    • "The systemic inflammatory response causes tissue damage in the lung, which is the most insidious component in sepsis due to compromised gas exchange. Despite modern treatment modalities, the mortality of these patients remains high in intensive care units (Cuthbertson et al., 2009; Schramm et al., 2011; Yano et al., 2006). Thus, there is an urgent need to develop more specific and effective therapies for patients with sepsis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Leukocyte accumulation is a rate-limiting step in inflammatory lung injury. The aim of this study was to define the role of CD11a/CD18 and CD11b/CD18 in sepsis-induced leukocyte rolling and adhesion in lung arterioles, capillaries and venules in male C57BL/6 mice using intravital fluorescence microscopy. Cecal ligation and puncture (CLP) markedly increased leukocyte rolling in arterioles and venules but not in capillaries in the lung. Immunoneutralization of CD11a, but not CD11b, decreased CLP-provoked leukocyte rolling in lung arterioles. Inhibition of CD11a or CD11b abolished CLP-induced arteriolar and venular leukocyte adhesion. Immunoneutralization of CD11a and CD11b reduced sepsis-induced leukocyte sequestration in pulmonary capillaries. Moreover, blocking CD11a or CD11b function improved microvascular blood flow in the lung of CLP animals. Considered together, our novel findings show that CD11a and CD11b mediate leukocyte adhesion in both arterioles and venules as well as trapping in capillaries in the lung. In addition, our data demonstrate that CD11a but not CD11b supports leukocyte rolling in pulmonary arterioles. Thus, these findings elucidate the molecular mechanisms behind leukocyte-endothelium interactions in the lung during systemic inflammation.
    European Journal of Pharmacology 02/2013; DOI:10.1016/j.ejphar.2013.01.024 · 2.53 Impact Factor
Show more